Skip to Main Content

Paper Details

Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33.
Pathology
7
2013
17q21, CONCLUSIONS, ERBB2, ERBB2+, PHB, Prohibitin, basal-like and luminal B cancers, breast cancer, chromosome 17q21, ductal carcinoma in situ of the breast, high grade, invasive breast cancers
Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Chromosomes, Human, Pair 17, Female, Gene Amplification, Gene Dosage, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Prohibitins, Repressor Proteins
Author NameAffiliation
Lucy R WebsterSydney Medical School - Westmead, University of Sydney, Westmead +Westmead Institute for Cancer Research, Westmead ++Westmead Millennium Institute, Institute of Clinical Pathology and Medical Research, Westmead Hospital, St Vincent's Hospital, Darlinghurst Prince of Wales Clinical School, University of New South Wales, Randwick ++School of Medical Sciences University of New South Wales, Charles Sturt University, National Cancer Institute
Lucy R WebsterSydney Medical School - Westmead, University of Sydney, Westmead +Westmead Institute for Cancer Research, Westmead ++Westmead Millennium Institute, Institute of Clinical Pathology and Medical Research, Westmead Hospital, St Vincent's Hospital, Darlinghurst Prince of Wales Clinical School, University of New South Wales, Randwick ++School of Medical Sciences University of New South Wales, Charles Sturt University, National Cancer Institute
  • 1 - 2

Datasets

Release 1.2